Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INBX Inhibrx Biosciences

已收盘 12-16 16:00:00 EST

81.57

+5.36

+7.03%

盘后79.95

-1.62-1.99%

18:31 EST

最高81.99	最低75.00	成交量35.21万
今开75.88	昨收76.21	日振幅9.17%
总市值11.86亿	流通市值6.37亿	总股本1,454万
成交额2,759万	换手率4.51%	流通股本780.85万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INBX","market":"US","secType":"STK","nameCN":"Inhibrx Biosciences","latestPrice":81.57,"timestamp":1765918800000,"preClose":76.21,"halted":0,"volume":352102,"hourTrading":{"tag":"盘后","latestPrice":79.95,"preClose":81.57,"latestTime":"18:31 EST","volume":133731,"amount":10906382.016,"timestamp":1765927877273},"delay":0,"floatShares":7808544,"shares":14543738,"eps":-10.025164,"marketStatus":"已收盘","change":5.36,"latestTime":"12-16 16:00:00 EST","open":75.88,"high":81.99,"low":75,"amount":27591806.348812,"amplitude":0.09172,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.025164,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765962000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":76.21,"preHourTrading":{"tag":"盘前","latestPrice":76.56,"preClose":76.21,"latestTime":"08:05 EST","volume":5731,"amount":437106.98053,"timestamp":1765890323989},"postHourTrading":{"tag":"盘后","latestPrice":79.95,"preClose":81.57,"latestTime":"18:31 EST","volume":133731,"amount":10906382.016,"timestamp":1765927877273},"volumeRatio":1.478147,"impliedVol":1.5024,"impliedVolPercentile":0.824},"requestUrl":"/m/hq/s/INBX/wiki","defaultTab":"wiki","newsList":[{"id":"1197504426","title":"Inhibrx Biosciences 更新 Inbrx-106 计划及 Ozekibart (Inbrx-109) 扩展队列的进展情况","url":"https://stock-news.laohu8.com/highlight/detail?id=1197504426","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197504426?lang=zh_cn&edition=full","pubTime":"2025-12-17 06:00","pubTimestamp":1765922409,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences 更新 Inbrx-106 计划及 Ozekibart (Inbrx-109) 扩展队列的进展情况","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2580739487","title":"Inhibrx Biosciences, Inc.盘中异动 大幅下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580739487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580739487?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:30","pubTimestamp":1762180241,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日22时30分，Inhibrx Biosciences, Inc.股票出现波动，股价急速下跌5.00%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Tharimmune, Inc.、Phio Pharmaceuticals Corp.、Terns Pharmaceuticals, Inc.涨幅较大，Phio Pharmaceuticals Corp.、Biodexa Pharmaceuticals Plc、Tharimmune, Inc.较为活跃，换手率分别为1405.48%、334.74%、271.30%，振幅较大的相关个股有Ethzilla Corporation C/Wts 06/11/2025、Revelation Biosciences Inc C/Wts 10/01/2027 、Terns Pharmaceuticals, Inc.，振幅分别为62.77%、12.71%、11.50%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322304294ec5447&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110322304294ec5447&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2579101742","title":"创胜集团-B(06628)合作伙伴Inhibrx公布ozekibart治疗软骨肉瘤的 II期临床试验积极结果，计划于2026年递交BLA的业绩进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101742","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579101742?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:57","pubTimestamp":1761865051,"startTime":"0","endTime":"0","summary":"基于该结果，Inhibrx计划于 2026年6月底前向美国监管机构递交ozekibart软骨肉瘤适应症的上市许可申请。据悉，Ozekibart是首个在随机对照试验中显著改善软骨肉瘤患者PFS的在研药物，目前该疾病尚无任何获批的系统性治疗方案。除注册性临床试验外，Inhibrx还在推进ozekibart的扩展队列，评估其与基于伊立替康的方案联合用于尤文肉瘤及结直肠癌的治疗。早期结果显示出令人鼓舞的信号，支持进一步探索ozekibart在这些医疗需求远未得到满足的难治性肿瘤中的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06628","INBX","BK4139"],"gpt_icon":0},{"id":"1133038553","title":"Inhibrx Biosciences股价在Ozekibart注册试验结果公布后，延长交易中上涨72.88%，至49.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133038553","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133038553?lang=zh_cn&edition=full","pubTime":"2025-10-24 05:18","pubTimestamp":1761254290,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences股价在Ozekibart注册试验结果公布后，延长交易中上涨72.88%，至49.03美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"1123415989","title":"Inhibrx Biosciences公布了其在软骨肉瘤的Ozekibart (Inbrx-109)注册试验中的积极顶线结果，并提供了对结直肠癌和尤文肉瘤扩展队列的最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1123415989","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123415989?lang=zh_cn&edition=full","pubTime":"2025-10-24 04:06","pubTimestamp":1761249977,"startTime":"0","endTime":"0","summary":"Inhibrx Biosciences公布了其在软骨肉瘤的Ozekibart (Inbrx-109)注册试验中的积极顶线结果，并提供了对结直肠癌和尤文肉瘤扩展队列的最新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"1112215836","title":"Inhibrx将召开网络研讨会，发布其在软骨肉瘤中Ozekibart（Inbrx-109）注册试验的顶线结果，并提供结直肠癌和尤文肉瘤扩展队列的最新消息","url":"https://stock-news.laohu8.com/highlight/detail?id=1112215836","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112215836?lang=zh_cn&edition=full","pubTime":"2025-10-23 04:02","pubTimestamp":1761163333,"startTime":"0","endTime":"0","summary":"Inhibrx将召开网络研讨会，发布其在软骨肉瘤中Ozekibart（Inbrx-109）注册试验的顶线结果，并提供结直肠癌和尤文肉瘤扩展队列的最新消息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2575619112","title":"Inhibrx Biosciences, Inc.盘中异动 急速拉升5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575619112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575619112?lang=zh_cn&edition=full","pubTime":"2025-10-14 00:01","pubTimestamp":1760371306,"startTime":"0","endTime":"0","summary":"北京时间2025年10月14日00时01分，Inhibrx Biosciences, Inc.股票出现波动，股价大幅拉升5.34%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014000146972b8f24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014000146972b8f24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2570085907","title":"Inhibrx Biosciences, Inc.盘中异动 早盘股价大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570085907","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570085907?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:09","pubTimestamp":1758895752,"startTime":"0","endTime":"0","summary":"北京时间2025年09月26日22时09分，Inhibrx Biosciences, Inc.股票出现波动，股价快速上涨5.45%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Plus Therapeutics, Inc.、Applied Therapeutics, Inc.、Crinetics Pharmaceuticals, Inc.涨幅较大，Soligenix, Inc.、Onconetix, Inc.、Fractyl Health, Inc.较为活跃，换手率分别为91.09%、76.85%、67.78%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 、Applied Therapeutics, Inc.、Curanex Pharmaceuticals Inc，振幅分别为29.41%、26.03%、25.04%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926220912954716ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926220912954716ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2561486216","title":"Inhibrx Biosciences, Inc.盘中异动 下午盘股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561486216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561486216?lang=zh_cn&edition=full","pubTime":"2025-08-21 03:13","pubTimestamp":1755717201,"startTime":"0","endTime":"0","summary":"北京时间2025年08月21日03时13分，Inhibrx Biosciences, Inc.股票出现异动，股价快速拉升5.39%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.99%。其相关个股中，Tharimmune, Inc.、Novabay Pharmaceuticals, Inc.、Radiopharm Theranostics Limited涨幅较大，Tharimmune, Inc.、Novabay Pharmaceuticals, Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为5449.39%、2844.17%、466.86%，振幅较大的相关个股有Tharimmune, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Windtree Therapeutics, Inc.，振幅分别为192.31%、100.00%、81.79%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082103132194f0636d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082103132194f0636d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INXB","INBX","BK4139"],"gpt_icon":0},{"id":"2555290590","title":"Inhibrx Biosciences, Inc.盘中异动 下午盘股价大跌5.46%报22.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555290590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555290590?lang=zh_cn&edition=full","pubTime":"2025-07-31 03:22","pubTimestamp":1753903353,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日03时22分，Inhibrx Biosciences, Inc.股票出现波动，股价急速下跌5.46%。截至发稿，该股报22.94美元/股，成交量5.0501万股，换手率0.35%，振幅7.01%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731032233a46c06ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731032233a46c06ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INXB","BK4139","INBX"],"gpt_icon":0},{"id":"2555006841","title":"Inhibrx Biosciences, Inc.盘中异动 临近午盘快速下挫5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555006841","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555006841?lang=zh_cn&edition=full","pubTime":"2025-07-29 23:55","pubTimestamp":1753804502,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日23时55分，Inhibrx Biosciences, Inc.股票出现异动，股价急速跳水5.26%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507292355039725bcb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507292355039725bcb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INXB","BK4139","INBX"],"gpt_icon":0},{"id":"2554777534","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554777534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554777534?lang=zh_cn&edition=full","pubTime":"2025-07-28 21:56","pubTimestamp":1753710974,"startTime":"0","endTime":"0","summary":"北京时间2025年07月28日21时56分，Inhibrx Biosciences, Inc.股票出现波动，股价大幅拉升5.11%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728215614972356a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728215614972356a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INXB","BK4139","INBX"],"gpt_icon":0},{"id":"2551138353","title":"Inhibrx Biosciences, Inc.盘中异动 快速拉升5.14%报22.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551138353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551138353?lang=zh_cn&edition=full","pubTime":"2025-07-15 00:55","pubTimestamp":1752512128,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日00时55分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅拉升5.14%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715005528a44a6846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715005528a44a6846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2550396305","title":"Inhibrx Biosciences, Inc.盘中异动 下午盘快速拉升5.27%报22.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550396305","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550396305?lang=zh_cn&edition=full","pubTime":"2025-07-12 01:56","pubTimestamp":1752256592,"startTime":"0","endTime":"0","summary":"北京时间2025年07月12日01时56分，Inhibrx Biosciences, Inc.股票出现异动，股价急速上涨5.27%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.60%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712015632a6a44be1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712015632a6a44be1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2550668205","title":"Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大涨5.02%报20.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550668205","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550668205?lang=zh_cn&edition=full","pubTime":"2025-07-10 03:51","pubTimestamp":1752090685,"startTime":"0","endTime":"0","summary":"北京时间2025年07月10日03时51分，Inhibrx Biosciences, Inc.股票出现波动，股价快速拉升5.02%。截至发稿，该股报20.94美元/股，成交量21.3176万股，换手率1.47%，振幅6.75%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.55%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710035125a69ff82b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710035125a69ff82b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2549551431","title":"Inhibrx Biosciences, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549551431","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549551431?lang=zh_cn&edition=full","pubTime":"2025-07-08 00:48","pubTimestamp":1751906911,"startTime":"0","endTime":"0","summary":"北京时间2025年07月08日00时48分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅拉升5.02%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.61%。其相关个股中，Mustang Bio, Inc.、Pelthos Therapeutics Inc.、Artelo Biosciences, Inc.涨幅较大，Mustang Bio, Inc.、Artelo Biosciences, Inc.、Sonnet Biotherapeutics Holdings, Inc.较为活跃，换手率分别为5766.35%、1206.19%、885.11%，振幅较大的相关个股有Mustang Bio, Inc.、Pelthos Therapeutics Inc.、Artelo Biosciences, Inc.，振幅分别为306.72%、233.18%、84.08%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708004831a43c352e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708004831a43c352e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2548886378","title":"Inhibrx Biosciences, Inc.盘中异动 大幅拉升5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548886378","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548886378?lang=zh_cn&edition=full","pubTime":"2025-07-02 00:14","pubTimestamp":1751386470,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日00时14分，Inhibrx Biosciences, Inc.股票出现波动，股价大幅拉升5.33%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.41%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702001430a728ca71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702001430a728ca71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2517645901","title":"Inhibrx Biosciences, Inc.盘中异动 大幅下跌5.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517645901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517645901?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:25","pubTimestamp":1741274709,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时25分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅跳水5.99%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.53%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306232509a2629e6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INBX","BK4139"],"gpt_icon":0},{"id":"2516677324","title":"Inhibrx Biosciences, Inc.盘中异动 早盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677324","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677324?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099056,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分，Inhibrx Biosciences, Inc.股票出现波动，股价急速跳水5.01%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422373696394681&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2516030626","title":"Inhibrx Biosciences, Inc.盘中异动 急速上涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516030626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516030626?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:21","pubTimestamp":1740774085,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时21分，Inhibrx Biosciences, Inc.股票出现波动，股价快速上涨5.52%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301042126abe138c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibrx.com","stockEarnings":[{"period":"1week","weight":-0.185},{"period":"1month","weight":-0.0369},{"period":"3month","weight":1.8683},{"period":"6month","weight":4.0105},{"period":"1year","weight":4.2127},{"period":"ytd","weight":3.9487}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inhibrx Biosciences, Inc.于2024年1月8日根据特拉华州法律成立，是Inhibrx, Inc.的直接全资子公司。该公司是一家临床阶段的生物制药公司，拥有一系列新型候选生物治疗药物，使用其专有的模块化蛋白质工程平台开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.100441},{"month":2,"riseRate":0,"avgChangeRate":-0.118883},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108872},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034815},{"month":5,"riseRate":0.25,"avgChangeRate":-0.039218},{"month":6,"riseRate":0.666667,"avgChangeRate":0.088726},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111417},{"month":8,"riseRate":1,"avgChangeRate":0.030836},{"month":9,"riseRate":0.75,"avgChangeRate":0.016607},{"month":10,"riseRate":0.5,"avgChangeRate":0.197255},{"month":11,"riseRate":0.75,"avgChangeRate":0.223807},{"month":12,"riseRate":0.75,"avgChangeRate":0.232405}],"exchange":"NASDAQ","name":"Inhibrx Biosciences","nameEN":"Inhibrx Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inhibrx Biosciences,INBX,Inhibrx Biosciences股票,Inhibrx Biosciences股票老虎,Inhibrx Biosciences股票老虎国际,Inhibrx Biosciences行情,Inhibrx Biosciences股票行情,Inhibrx Biosciences股价,Inhibrx Biosciences股市,Inhibrx Biosciences股票价格,Inhibrx Biosciences股票交易,Inhibrx Biosciences股票购买,Inhibrx Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibrx Biosciences(INBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inhibrx Biosciences(INBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}